Trial Profile
A Phase 1 Randomized, Observer Blind, Placebo Controlled, Dosage-Escalation Single Center Study to Evaluate the Safety and Immunogenicity of an RSV Fusion Glycoprotein (F) Subunit Vaccine in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs RSV F protein subunit vaccine GlaxoSmithKline (Primary) ; Aluminium hydroxide; MF 59
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK; Novartis Vaccines
- 12 Apr 2019 Results published in the Vaccine
- 25 Apr 2017 Status changed from active, no longer recruiting to completed.
- 25 Jul 2016 Status changed from recruiting to active, no longer recruiting.